Related Guides
Deeper context, comparisons, and practical research paths.
Compound Profile
Semaglutide
GLP-1 receptor agonist (prescription drug)
Semaglutide is a GLP 1 receptor agonist, FDA approved as Ozempic, Wegovy, and Rybelsus, backed by a large multi trial Phase 3 program spanning weight management, type 2 diabetes, cardiovascular risk reduction, and kidney outcomes — a categorically stronger evidence tier than the RUO peptides elsewhere in this series.
Use extra caution — Common side effects are nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation. Details
Last reviewed: Report a correctionProfile-wide ·Unassigned
At a glance
From this profile's structured data- Evidence
- Editorial grade not demonstrated by recorded studies
- Safety
- Common side effects are nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation.
- Profile context
- GLP-1 Receptor Agonism, Glucose-Dependent Insulin Secretion, Glucagon Suppression
Next stepsWhere to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
Prescription drug: approved-product and compounding rules are separate
Semaglutide is used in FDA-approved prescription products including Ozempic, Wegovy, and Rybelsus. FDA determined the semaglutide injection shortage was resolved on February 21, 2025, so shortage-based enforcement discretion for routine essentially-copy compounding has ended; 503A and 503B still operate under different statutory conditions.
- 503A patient-specific compounding is subject to conditions including restrictions on regularly or inordinate amounts making products that are essentially copies of commercially available drugs.
- FDA states semaglutide is not currently on the 503B bulks list and is not on the drug-shortage list; FDA’s April 30, 2026 proposal to exclude it from the 503B bulks list is a proposal, not a final blanket rule.
- Compounded semaglutide is not FDA-approved and does not automatically inherit the approved products’ quality or clinical evidence.
Regulatory status
2026 federal and state regulatory context
FDA approved and commercially available by prescription. The FDA has determined semaglutide is no longer in shortage, curtailing 503B outsourcing facilities' ability to compound it in bulk; compounded access now generally requires individualized physician documented clinical necessity rather than cost or availability alone. Not sold as a research peptide.
Regulatory changelog
- 2026: FDA shortage determination resolved for semaglutide, winding down the compounded supply era; 503B bulk compounding no longer available absent individualized clinical justification.
Quick stats
- Evidence level
- Needs review
- Typical onset
- Varies by prep
- Safety rating
- Use extra caution: Use caution
- Best for
- GLP 1 Receptor Agonism, Glucose Dependent Insulin Secretion, Glucagon Suppression
- Avoid / review if
- Pregnancy/Breastfeeding, History Of Pancreatitis, Severe Gastrointestinal Disease Or Gastroparesis
Safety
Safety & Cautions
Common side effects are nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation. Less common but notable: gallbladder disease, rare pancreatitis, and aspiration risk under anesthesia due to delayed gastric emptying.
High caution
Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.
- Hormonal Activity ContextHormone-adjacent wording is present and should be interpreted carefully.
- Stimulant-Like ProfileStimulant-like or activating caution language is present.
- Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.
Evidence-based safety
Caution when combined
Severity and certainty are shown separately. A high-priority caution can still be theoretical: these pairings are screened from shared contraindication mechanisms and are not automatically documented clinical interactions. Provenance identifies the source fields that produced each flag; it does not upgrade the certainty of the pairwise claim.
Moderate Caution
110 flagged pairingsBlood-sugar lowering
Moderate Caution
110 flagged pairingsBlood-sugar lowering
Representative pairings are shown below. Large mechanism groups are intentionally summarized to keep profiles focused and crawl-efficient.
Blood-sugar loweringCertainty: Theoretical
Data provenance recorded for 110 of 110 pairings in this mechanism group.
- Acarbose — Theoretical interaction certainty
- ajoene — Theoretical interaction certainty
- Allicin — Theoretical interaction certainty
- Aloe Vera — Theoretical interaction certainty
- Alpha-Lipoic Acid — Theoretical interaction certainty
- American Ginseng Extract — Theoretical interaction certainty
- Andrographis — Theoretical interaction certainty
- Anemarrhena Asphodeloides — Theoretical interaction certainty
- Tarragon — Theoretical interaction certainty
- Ashoka — Theoretical interaction certainty
- Astragalus — Theoretical interaction certainty
- Astragalus Membranaceus — Theoretical interaction certainty
+98 more pairings share this mechanism. Use the Safety Checker to review a specific combination.
Evidence Summary
Profile-wide ·UnassignedEvidence lens
Treat this profile as unresolved until source review is complete.
Needs reviewNeeds review
Human clinical evidence: Not the primary signal
Mechanistic / preclinical: Mechanism mapped — GLP 1 Receptor Agonism · Glucose Dependent Insulin Secretion · Glucagon Suppression
Research maturity: Theoretical / mechanistic research — Mechanistic or unresolved evidence is kept separate from established human outcomes.
Safety boundary: Safety note available — Common side effects are nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation.
Evidence Strength
Confidence estimate based on the design quality and consistency of published clinical trials.
Semaglutide has an evidence rating that is still under review.
General wellnessGeneral wellness
Effects
4
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
How Semaglutide Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How Semaglutide Works
CompoundTarget / ReceptorMechanismEffect / Outcome
Dosing
- No standardized dose
- No established consumer dosing protocol; see full guide article for regulatory and safety context.
Mechanisms & biological pathways
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
- GLP 1 Receptor Agonism
- Glucose Dependent Insulin Secretion
- Glucagon Suppression
- Central Appetite Regulation
- Incretin Signaling
Continue exploring
Related research paths
Related Safety Pages
Safety checks and cautions relevant to this decision.
Related Compounds
Compounds connected by the same goals, effects, or research topics.
Related Herbs
Botanicals connected by the same goals, effects, or research topics.
Related Articles
Deeper context, comparisons, and practical research paths.
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the Semaglutide evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Sourcing options disabled for safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions above under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?
Compound profile context
How to interpret Semaglutide
Semaglutide compound profile with evidence context, key research topics, source notes, safety context, and references presented in an evidence-first… Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing Semaglutide, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.